RUA vs. NCYT, POLX, IHC, AVO, SUN, MHC, BELL, DEMG, NIOX, and SN
Should you be buying RUA Life Sciences stock or one of its competitors? The main competitors of RUA Life Sciences include Novacyt (NCYT), Polarean Imaging (POLX), Inspiration Healthcare Group (IHC), Advanced Oncotherapy (AVO), Surgical Innovations Group (SUN), MyHealthChecked (MHC), Belluscura (BELL), Deltex Medical Group (DEMG), NIOX Group (NIOX), and Smith & Nephew (SN). These companies are all part of the "medical devices" industry.
RUA Life Sciences vs. Its Competitors
Novacyt (LON:NCYT) and RUA Life Sciences (LON:RUA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, dividends, risk, valuation, analyst recommendations, institutional ownership and media sentiment.
In the previous week, Novacyt had 1 more articles in the media than RUA Life Sciences. MarketBeat recorded 1 mentions for Novacyt and 0 mentions for RUA Life Sciences. Novacyt's average media sentiment score of 1.75 beat RUA Life Sciences' score of 0.00 indicating that Novacyt is being referred to more favorably in the media.
RUA Life Sciences has a net margin of -65.72% compared to Novacyt's net margin of -203.06%. RUA Life Sciences' return on equity of -26.38% beat Novacyt's return on equity.
RUA Life Sciences has lower revenue, but higher earnings than Novacyt. RUA Life Sciences is trading at a lower price-to-earnings ratio than Novacyt, indicating that it is currently the more affordable of the two stocks.
0.1% of Novacyt shares are owned by institutional investors. Comparatively, 26.0% of RUA Life Sciences shares are owned by institutional investors. 3.1% of Novacyt shares are owned by insiders. Comparatively, 51.3% of RUA Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Novacyt has a beta of -1.86, meaning that its share price is 286% less volatile than the S&P 500. Comparatively, RUA Life Sciences has a beta of 1.21, meaning that its share price is 21% more volatile than the S&P 500.
Summary
RUA Life Sciences beats Novacyt on 9 of the 13 factors compared between the two stocks.
Get RUA Life Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for RUA and its competitors with MarketBeat's FREE daily newsletter.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
RUA Life Sciences Competitors List
Related Companies and Tools
This page (LON:RUA) was last updated on 7/7/2025 by MarketBeat.com Staff
